ReShape Lifesciences EPS - Earnings per Share 2015-2024 | RSLS
ReShape Lifesciences eps - earnings per share from 2015 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| ReShape Lifesciences Annual EPS | |
|---|---|
| 2024 | $-13.83 |
| 2023 | $-110.87 |
| 2022 | $-6,331.40 |
| 2021 | $-16,800.58 |
| 2020 | $-16,104.65 |
| 2019 | $-43,870.67 |
| 2018 | $-171,296.20 |
| 2017 | $-181,413.50 |
| 2016 | $-423,007.40 |
| 2015 | $-2,367,097.00 |
| 2014 | $-1,623,128.00 |
| ReShape Lifesciences Quarterly EPS | |
|---|---|
| 2024-12-31 | $-2.00 |
| 2024-09-30 | $-3.11 |
| 2024-06-30 | $-3.49 |
| 2024-03-31 | $-5.23 |
| 2023-12-31 | $101.98 |
| 2023-09-30 | $-59.36 |
| 2023-06-30 | $-62.79 |
| 2023-03-31 | $-90.70 |
| 2022-12-31 | $-2,068.02 |
| 2022-09-30 | $-1,570.35 |
| 2022-06-30 | $-1,421.51 |
| 2022-03-31 | $-1,271.51 |
| 2021-12-31 | $-7,672.67 |
| 2021-09-30 | $-3,023.26 |
| 2021-06-30 | $-2,500.00 |
| 2021-03-31 | $-3,604.65 |
| 2020-12-31 | $-4,824.99 |
| 2020-09-30 | $-3,837.21 |
| 2020-06-30 | $-1,511.63 |
| 2020-03-31 | $-5,930.83 |
| 2019-12-31 | $14,739.85 |
| 2019-09-30 | $-5,320.30 |
| 2019-06-30 | $-21,978.94 |
| 2019-03-31 | $-31,311.27 |
| 2018-12-31 | $-29,392.48 |
| 2018-09-30 | $-30,264.66 |
| 2018-06-30 | $-49,714.27 |
| 2018-03-31 | $-61,924.80 |
| 2017-12-31 | $-52,330.79 |
| 2017-09-30 | $-47,969.92 |
| 2017-06-30 | $-40,120.29 |
| 2017-03-31 | $-40,992.47 |
| 2016-12-31 | $1,219,308.00 |
| 2016-09-30 | $-476,210.40 |
| 2016-06-30 | $-623,608.90 |
| 2016-03-31 | $-542,496.10 |
| 2015-12-31 | $0.00 |
| 2015-09-30 | $-541,623.90 |
| 2015-06-30 | $0.00 |
| 2014-12-31 | $0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.005B | $0.008B |
| ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA. | |||